SURESH RAMALINGAM, MD of the Winship Cancer Institute of Emory University talks about the CheckMate 057 trial in non-squamous and the CheckMate 017 trial in squamous cell NSCLC of nivolumab versus docetaxel
Advertisement
CheckMate 057 trial in non-squamous and the CheckMate 017 trial in squamous cell NSCLC of nivolumab versus docetaxel
By Editor